31.86 0.00 (0.00%)
After hours: 7:55PM EDT
Commodity Channel Index
|Bid||31.83 x 1000|
|Ask||31.99 x 1000|
|Day's Range||31.32 - 32.92|
|52 Week Range||11.54 - 36.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.63|
A novel coronavirus (COVID-19) vaccine developed and approved in a rush may prove to be unsafe, according to International Vaccine Institute Director-General Jerome Kim.What Happened "We don't know that a vaccine that's developed in four months -- or I guess 12 to 18 months, which is the current estimate -- is really safe," Kim told CNBC, as reported Thursday.According to Kim, it takes anywhere between five to 10 years to roll out vaccines using typical procedures.Kim further told CNBC that there had been a special urgency to develop a vaccine for COVID-19, with a majority of countries suffering the outbreak, and that has resulted in a "significant amount of funding" for pharmaceutical companies to develop a vaccine.It's "really a remarkable thing," the IVI head said, but warned that 93% of the vaccines fail clinical trials.Moderna Inc. (NASDAQ: MRNA) was the first company to begin clinical trials of its COVID-19 vaccine in April, followed recently by Inovio Pharmaceuticals Inc. (NASDAQ: INO). The phase one trial of Johnson & Johnson (NYSE: JNJ) is also expected to begin later this year.When asked about President Donald Trump's claim that antimalarial drugs hydroxychloroquine and chloroquine are helping for coronavirus patients, Kim told CNBC that more research and evidence is needed."We are going to hope to test this to make sure that either this allows people to get off ventilators quickly...or it keeps people out of hospitals..or that it decreases the period of time that a patient is infectious," Kim said, adding that the concern isn't just over the drug's safety.See more from Benzinga * Microsoft Delays Launch Of Dual-Screen Surface Neo To Next Year * 'I Am Trying To Get More Cash': Why Mark Cuban Isn't Hopeful On US Market Rally * Sen. Kelly Loeffler Will Liquidate Stocks 'To End The Distraction' Following Insider Trading Controversy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale
The U.S. reached a grim milestone on Monday, passing 10,000 coronavirus-related deaths, and according to a prominent physician, the nation won’t move beyond the crisis without a vaccine.
Seemingly hopeful news came out of New York Monday, which could be nearing its apex of the novel coronavirus crisis, while markets opened higher to start a week that could see other metro areas surge in cases and deaths.
Vir Biotechnology soars after GlaxoSmithKline says it will invest $250 million in the biotech company.
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.
A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -
On CNBC's "Options Action", Mike Khouw shared with the viewers his options trading idea for Moderna Inc (NASDAQ: MRNA), the company that is currently leading the race for a COVID-19 vaccine.The stock is trading close to its all-time high and the options premiums in the name are elevated, so Khouw wants to make a bullish bet by selling the May $30/$28 put spread for a credit of 80 cents. If the stock stays above $30 at the May expiration, Khouw is going to collect the premium. The trade starts to lose money below $29.20 and in case of a pullback to $28 or lower it would reach its maximal loss of $1.20.Extreme market volatility has pulled the rug out from under a lot of traders. Attend the virtual Benzinga Options Boot Camp to learn to trade options in a volatile market and start going after solid trades with absolute confidence. Register for FREE at benzingabootcamp.com before space fills up!See more from Benzinga * Tony Zhang's Nike Trade * Analysts Share Stocks They Would Buy In This Environment: Exxon Mobil, P&G And More * PIMCO CIO Says To Buy What The Fed Is Buying(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The biotech’s shares are on the rise, and so are automated sales of Moderna shares through plans set up by company insiders.
Shares of some of the world's best companies have been cut down amid the current crisis. Hilton Worldwide (NYSE:HLT) is no exception. Hilton stock has dropped a stunning 46% from its peak.Source: josefkubes / Shutterstock.com The fall is a classic case of the market weighing short-term fears too heavily. Of course Hilton is going to take a hit from the response to the coronavirus pandemic. But, again, its share price has been cut almost in half.That type of decline isn't justified by demand that is reduced for a few months. In fact, it's not even justified by an impact that lasts a few years.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe impact won't last a few years. This crisis will pass. The economy will recover. We will make it through. On the other side, consumers will want to travel and likely want to do so soon. (I'm surely not the only one with a strong case of 'cabin fever' at the moment.) * 7 Telecom Stocks That Are Worth a Close Look I'm not dismissing the very real human toll the coronavirus is taking. But the U.S. economy, and U.S. stocks, will come back stronger than ever. In the meantime, investors have the opportunity to own some of the world's best businesses at a steep discount to fair value.Hilton is one of those businesses. Hilton stock is one of those names priced at a discount. Don't PanicIt's understandable why investors have sold Hilton stock. Panic still grips this market, even with a recent bounce. The volatility index, often referred to as the VIX, still sits above 50 -- a hugely elevated level.And like other hotels, Hilton is seeing a significant short-term reduction in demand. One industry analyst estimated that RevPAR (revenue per available room) was down a stunning 80% last week.There are mid-term worries as well. Some investors clearly are worried that a recession will follow even once the coronavirus is under control. And Hilton unsurprisingly struggled during the financial crisis.According to the prospectus filed at the time of its 2013 initial public offering, revenue declined almost 15% in 2009. Excluding non-cash impairments, operating profit fell by almost half.Hilton is going to take a hit. But that's true of most companies in the short term. There are exceptions like Zoom Video Technologies (NASDAQ:ZM), or a biotech like Moderna (NASDAQ:MRNA) that is working on a coronavirus vaccine. A travel-based company like Hilton, however, simply is going to have to make it through to the other side. Look at HistoryAnd Hilton will make it through to the other side. Bear in mind that the company is a franchisor, which significantly minimizes its exposure to hotel-level operating losses during this pandemic.Hilton did close 2019 with almost $8 billion in debt. But with a market capitalization still over $18 billion and the power of the Hilton brand, those liabilities are manageable.Meanwhile, travel will bounce back. And corporate travel should do so first. That's Hilton's sweet spot.We've seen what happens with hotel stocks in a recovery. Hilton was private during the financial crisis: Blackstone Group (NYSE:BX) led a leveraged buyout in 2007. But peers were among the best stocks to buy at -- or even before -- the March 2009 bottom.Marriott (NASDAQ:MAR) more than tripled in 20 months. Hyatt (NYSE:H) executed an IPO in late 2009 and the stock almost doubled in 15 months. The Case for Hilton StockI'm not guaranteeing that Hilton stock will see similar returns. But in a recovery, hotel stocks do well. And Hilton stock may well be the best hotel stock out there.Certainly, in this volatile market, position sizing matters. Investors need to do their due diligence. And it's possible HLT sees further declines.But, as is always the case, investors need to take the long view. This is one of the world's great companies. Its stock price is down by almost half.At some point, one of those two things will change. It won't be the quality of Hilton's business.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * This Stock Picker's Latest Video Just Went Viral * The 1 Stock All Retirees Must Own The post Hilton Stock Will Rally Once This Crisis Passes appeared first on InvestorPlace.
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
The second phase of the clinical trials of the novel coronavirus (COVID-19) vaccine of Moderna Inc. (NASDAQ: MRNA) could begin in spring, the biotechnology company's chairman Noubar Afeyan told CNBC on Thursday.What Happened "It's difficult to put a specific date on things just because it's a very dynamic situation," Afeyan said. "We've entered phase 1 trials. ... We'll enter hopefully phase 2 trials, we expect that to happen in the spring, perhaps early summer," Afeyan said. "And success there will hopefully lead us to phase 3 trials."Moderna's phase one clinical trial started on March 16, in collaboration with the National Institute of Health.White House Coronavirus Task Force member Anthony Fauci on Wednesday said that the trials were "on track," and the vaccine, if approved for use, could be available in the next 12 to 18 months.Other companies, including Johnson & Johnson (NYSE: JNJ) and Inovio Pharmaceuticals Inc. (NASDAQ: INO), have been working on developing their coronavirus vaccines as well.Afeyan told CNBC that Moderna hoped "that everybody succeeds because the worldwide demand for these types of interventions is far in excess of what any one player can deliver."Price Action Moderna's shares closed 11.9% higher at $33.20 on Thursday. The shared traded 0.27% lower at $33.11 in the after-hours session.See more from Benzinga * Tesla Is 'Crushing The Auto Industry', Munster Says, As Company Posts Q1 Delivery Figures * FTC Seeks To Undo Altria's .8B Juul Investment, Says It Violated Antitrust Laws * Disney+ Makes Middle East Debut Through Third-Party Network(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The Cambridge-based company set out to raise its seventh so-called Opportunity Fund in mid-January and managed to pull together $1.1 billion in funding within two months.
All hands are on deck in the medical sector amid the scramble for testing, treatments and vaccines for Covid-19. IBD tech reporter Allison Gatlin provides a detailed investor overview.